Q2 FY2026 EarningsQ2 FY26 results beat consensus on bottom-line metrics, reporting a GAAP net loss of -$17.8M vs. -$20.1M expected, and EPS of -$0.35 vs. -$0.36 expected. While R&D expenses rose to $12.9M due to Phase 3 LEVEL trial progress, disciplined SG&A and $13.4M in warrant proceeds bolstered the cash position to $118.0M. Management extended the cash runway through Q2 2028 and confirmed topline Phase 3 data is expected in August 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Tenax Therap(TENX) the Revenue is 0 (--%), Meet estimate;the EBIT is -18.78 M (-59.29%), Miss estimate;the EPS is -0.35 (-29.63%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B--
0.00B--
0.00B--%
EBITMiss expectations
-0.02B59.29%
-0.02B48.33%
-0.00B10.96%
EPSExceed expectations
-0.3529.63%
-0.361433.86%
+0.01144.23%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf